Trump policies, China's biotech boom are ending Europe's pharma powerhouse era

The article highlights long-standing concerns that Europe's fragmented capital markets, inconsistent single-market adoption on pricing and clinical trials, and uneven reimbursement policies are limiting companies. It is largely a structural critique rather than a company-specific or market-moving event. No new numerical developments or policy changes are reported.

Analysis

The article highlights long-standing concerns that Europe's fragmented capital markets, inconsistent single-market adoption on pricing and clinical trials, and uneven reimbursement policies are limiting companies. It is largely a structural critique rather than a company-specific or market-moving event. No new numerical developments or policy changes are reported.